ADVERTISEMENT
Sponsored
Special Report
Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia
06/10/2022
In an interview, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma (MZL) and Waldenström’s macroglobulinemia (WM).
Dr Gandhi further explains the connection of Bruton tyrosine kinase inhibitors with MZL and WM while examining data from various trials.
Current Issue
April 2024
Volume 10
Issue 2
Subscribe
Journal of Clinical Pathways Newsletter
